Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma

doi:10.5306/wjco.v15.i1.115

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4396)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

2494

Figures (1-5)

646

Tables (1-1)

223

Sum=3449

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

135

Download

252

Sum=387

Publishing Process of This Article

Item

Count

Browse

133

Download

327

Sum=460

Jan 24, 2024 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Clin Oncol. Jan 24, 2024; 15(1): 115-129
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.115

Full Size Figure Download Figure

Figure 5 Illustrated overview of ivermectin promoting apoptosis in t(4;14) multiple myeloma cells. IκBα: Anti-inhibitor of NF-κB; IKKs: Inhibitors of kappa B kinase; ROS: Reactive oxygen species.

Citation: Song Y, Zhang HJ, Song X, Geng J, Li HY, Zhang LZ, Yang B, Lu XC. Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma. World J Clin Oncol 2024; 15(1): 115-129
URL: https://www.wjgnet.com/2218-4333/full/v15/i1/115.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i1.115